PUBLICATIONS
20.11
2018
Presentation of theresults of the LDOS002 clinical trial at the 9th International Conference on Contemporary Oncology.
The results of a phase I / II clinical trials with dose escalation of the L-DOS47  immunoconjugate in monotherapy of patients with non-squamous, non-small cell lung cancer (LDOS002) were presented by Prof. Cezary Szczylik at the session
20.11
2018
Presentation of the first results of research and development works on V-DOS47 at AACR Annual Meeting 2018 in Chicago.
Dr Anna Bujak presented the first results of Helix Immuno-Oncology at AACR Annual Meeting 2018 in Chicago. We showed the anti-tumor effect of V-DOS47 in the syngeneic mouse model and no such effect in the immunodeficient model. These observations
21.08
2017
Development and characterization of a camelid single Domain antibody– Urease conjugate That Targets Vascular endothelial growth Factor receptor 2
Angiogenesis is the process of new blood vessel formation and is essential for a tumor to grow beyond a certain size. Tumors secrete the pro-angiogenic factor vascular endothelial growth factor, which acts upon local endothelial cells by binding to vascular endothelial growth factor receptors (VEGFRs). In this study, we describe the development and characterization of V21-DOS47, an immunoconjugate that targets VEGFR2. V21-DOS47 is composed of a camelid single domain anti-VEGFR2 antibody (V21) and the enzyme urease.